Latest Diet Drug Enthusiasm Likely to be Short-Lived

Agenda-Setting Financial Insight.
July 18 2012 4:46 PM

Latest Diet Drug Enthusiasm Likely to be Short-Lived

The latest surge of drug enthusiasm may last about as long as the typical diet.

Photo by PHILIPPE HUGUEN/AFP/Getty Images

Two U.S. biotech firms are bingeing on obesity drugs. Their concoctions for weight loss have both been approved by the Food and Drug Administration in the last month. With American obesity rates rocketing, analysts are eyeing fat sales and bankers are weighing mergers. 

Vivus, one of the producers, just got the OK for its drug Qsymia. The company’s market value has more than tripled since January to over $3 billion. Meanwhile the value of Arena Pharmaceuticals, whose Belviq was approved last month, has gone up five-fold. 

Yet it’s a stretch to think Vivus will ever sell $3.6 billion-worth of its drug every year, as Jefferies forecasts. In tests, users only lost 10 percent of their weight. Qsymia is composed of two cheap generic drugs already on the market, so doctors may just prescribe them separately. And side effects, such as an increased risk of birth defects, will probably limit sales. 

A big problem for all diet pills is that in the context of human history obesity has only very recently become, for some people, a bigger threat than starvation. There are good reasons why it’s difficult to curtail appetite or calorie absorption significantly. 

That’s one reason diet aids don’t often live up to expectations. Analysts thought GlaxoSmithKline’s Alli would bring in about $2 billion of annual sales, but customers never warmed to the incontinence-inducing product and sales are running much lower. Procter & Gamble’s fat substitute Olestra similarly raised expectations and then dashed them. 

Side-effects are another concern. Sanofi thought it could sell $3 billion of Acomplia per year, but withdrew the drug when it was linked to an increased risk of suicide. Abbott pulled Meridia due to the chance of stroke. And Wyeth took a charge in excess of $20 billion for lawsuits arising from its notorious fen-phen combination. 

Obesity is a serious problem for a growing number of people. And the new drugs may yet prove effective and safe enough that users stick with them. But the odds aren’t great. The biotechs may be smart, but tens of thousands of years of evolution have honed people’s appetite for the Baconator. The latest surge of drug enthusiasm may last about as long as the typical diet.

Read more at Reuters Breakingviews.


Robert Cyran moved from the London office to New York, where he covers global technology, pharmaceuticals and special situations. Rob began his career at Forbes magazine, where he assisted in the start-up of the international version of the magazine.



The Democrats’ War at Home

How can the president’s party defend itself from the president’s foreign policy blunders?

Secret Service Director Julia Pierson Resigns

Piper Kerman on Why She Dressed Like a Hitchcock Heroine for Her Prison Sentencing

Windows 8 Was So Bad That Microsoft Will Skip Straight to Windows 10

Homeland Is Good Again! For Now.


Cringing. Ducking. Mumbling.

How GOP candidates react whenever someone brings up reproductive rights or gay marriage.


How Even an Old Hipster Can Age Gracefully

On their new albums, Leonard Cohen, Robert Plant, and Loudon Wainwright III show three ways.

The U.S. Has a New Problem in Syria: The Moderate Rebels Feel Like We’ve Betrayed Them

We Need to Talk: A Terrible Name for a Good Sports Show by and About Women

Trending News Channel
Oct. 1 2014 1:25 PM Japanese Cheerleader Robots Balance and Roll Around on Balls
  News & Politics
Oct. 1 2014 4:15 PM The Trials of White Boy Rick A Detroit crime legend, the FBI, and the ugliness of the war on drugs.
Oct. 1 2014 2:16 PM Wall Street Tackles Chat Services, Shies Away From Diversity Issues 
The Eye
Oct. 1 2014 1:04 PM An Architectural Crusade Against the Tyranny of Straight Lines
  Double X
The XX Factor
Oct. 1 2014 4:05 PM Today in GOP Outreach to Women: You Broads Like Wedding Dresses, Right?
  Slate Plus
Behind the Scenes
Oct. 1 2014 3:24 PM Revelry (and Business) at Mohonk Photos and highlights from Slate’s annual retreat.
Brow Beat
Oct. 1 2014 3:02 PM The Best Show of the Summer Is Getting a Second Season
Future Tense
Oct. 1 2014 4:26 PM How to Measure the Value of Your Personal Data in Cookies: A Slate Guide
  Health & Science
Oct. 1 2014 4:03 PM Does the Earth Really Have a “Hum”? Yes, but probably not the one you’re thinking.
Sports Nut
Sept. 30 2014 5:54 PM Goodbye, Tough Guy It’s time for Michigan to fire its toughness-obsessed coach, Brady Hoke.